Skip to content

Gilead Sciences Inc Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Tue, Feb 9, 2027, after the market closes · estimates and history

Gilead Sciences Inc · E.GILD.MX · Mexico
Use symbol E.GILD.MX in our API & Excel add-in to retrieve this data ↓
3,235.00
(+0.04%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 37.44%

Gilead Sciences Inc Forecast

Gilead Sciences Inc short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 37.4% a year, a typical one-standard-deviation range is 3,064–3,406 over a week, 2,885–3,585 over a month and 2,024–4,446 over a year. (Signals as of 5 Nov 2026.)

Gilead Sciences Inc Price Chart

MacroFinance.ai

Gilead Sciences Inc Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Gilead Sciences Inc
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Gilead Sciences Inc
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Gilead Sciences Inc
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for Gilead Sciences Inc, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on Gilead Sciences Inc

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Gilead Sciences Inc Trading Strategies

28 backtested tactical asset allocation strategies hold EEM (emerging markets), the closest tradable exposure to Gilead Sciences Inc; 2 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

See all 28 strategies holding EEM →

Statistical Distribution of Returns

Plus

How Gilead Sciences Inc’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Gilead Sciences Inc behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Gilead Sciences Inc (Mexico)

Gilead Sciences Inc is a listed security in Mexico. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Gilead Sciences Inc

Frequently asked questions

What is Gilead Sciences Inc?
Gilead Sciences Inc is a listed security in Mexico. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Gilead Sciences Inc price?
The latest close is 3,235 (5 Nov 2026), +0.04% on the day. The price at the top of the page refreshes during the trading day.
Is Gilead Sciences Inc in an uptrend?
As of 5 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Gilead Sciences Inc?
20-day realised volatility is 37.4% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 10.8% over a month and 5.3% over a week.
What factors affect Gilead Sciences Inc?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Gilead Sciences Inc, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Gilead Sciences Inc?
28 backtested tactical asset allocation strategies trade Gilead Sciences Inc through EEM; 2 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Gilead Sciences Inc returns analysed?
The Statistical Distribution of Returns section shows the distribution of Gilead Sciences Inc daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Gilead Sciences Inc historical data?
In the Free historical data section of this page: the last 10 years of Gilead Sciences Inc daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Gilead Sciences Inc historical data (last 10 years)

Browse or instantly download the last 10 years of Gilead Sciences Inc daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.GILD.MX&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-193173.84
2026-11-183106.2
2026-11-173106.2
2026-11-133146.79
2026-11-123146.79
2026-11-113146.79
2026-11-103146.79
2026-11-093146.79
2026-11-063146.79
2026-11-053295
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company has a partnership with Pan American Health Organization (PAHO) to accelerate access to lenacapavir for HIV prevention as pre-exposure prophylaxis (PrEP) across all PAHO member states in Latin America and the Caribbean. The company was incorporated in 1987 and is headquartered in Foster City, California.